Table 1 The characteristics of patients
From: The efficacy of small molecule anti-angiogenic drugs in previously treated Thymic carcinoma
Characteristics, n (%) | Total (n = 17) | Apatinib (n = 13) | Anlotinib (n = 4) | P |
|---|---|---|---|---|
Age, median(range), yr | 59 (35–73) | 60 (35–73) | 58 (49–66) | 0.881* |
Sex, male/female | 10/7 (58.8 vs. 41.2) | 7/6 (53.8 vs. 46.2) | 2/2 (50.0 vs. 50.0) | 1.000** |
ECOG PS | 1.000** | |||
0 | 6 (35.3) | 5 (38.5) | 1 (25.0) | |
1 | 11 (64.7) | 8 (61.5) | 3 (75.0) | |
Smoking status | 0.538** | |||
Never | 12 (70.6) | 10 (76.9) | 2 (50.0) | |
Former or current | 5 (29.4) | 3 (23.1) | 2 (50.0) | |
WHO histology | 0.307** | |||
Squamous cell carcinoma | 10 (58.8) | 6 (46.2) | 4 (100.0) | |
Undifferentiated carcinoma | 3 (17.6) | 3 (23.1) | 0 (0.0) | |
Unavailable | 4 (23.5) | 4 (30.8) | 0 (0.0) | |
Masaoka-Koga stage | 1.000** | |||
IVA | 1 (5.9) | 1 (7.7) | 0 (0.0) | |
IVB | 16 (94.1) | 12 (92.3) | 4 (100.0) | |
Number of prior treat-line | 1.000** | |||
1 | 10 (58.8) | 8 (61.5) | 2 (50.0) | |
>1 | 7 (41.2) | 5 (38.5) | 2 (50.0) | |
Surgical Procedures | 0.541** | |||
Yes | 3 (17.6) | 3 (23.1) | 0 (0.0) | |
No | 14 (82.4) | 10 (76.9) | 4 (100.0) | |
Lung metastasis | 1.000** | |||
Yes | 13 (76.5) | 10 (76.9) | 3 (75.0) | |
No | 4 (23.5) | 3 (23.1) | 1 (25.0) | |
Liver metastasis | 0.584** | |||
Yes | 6 (35.3) | 4 (30.8) | 2 (50.0) | |
No | 11 (64.7) | 9 (69.2) | 2 (50.0) |